It remains unclear, however, whether <i>CDK12</i> loss <i>per se</i> is sufficient to drive prostate cancer development-either alone, or in the context of other genetic alterations-and whether <i>CDK12</i>-mutant tumors exhibit sensitivity to specific pharmacotherapies. This evidence concerns the gene CDK12 and prostate carcinoma.